Immunotherapeutic strategies for Alzheimer's disease treatment

TheScientificWorldJournal

Volumn 9, Issue , 2009, Pages 909-919

  Solomon, Beka ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Alzheimer's disease; Amyloid plaque; Amyloid ; Immunotherapy; Inflammation; Neuropathology

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-30]; AMYLOID BETA PROTEIN[1-42]; HISTIDYLARGINYLPHENYLALANYLGLUTAMIC ACID; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; INFLUENZA VACCINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 266; MONOCLONAL ANTIBODY BC05; PEPTIDE; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; AMNESIA; ANTIBODY RESPONSE; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; LEARNING DISORDER; MICROGLIA; NONHUMAN; PASSIVE IMMUNIZATION; PATHOGENESIS; PROTEIN CONFORMATION; REVIEW; SENILE PLAQUE; UNSPECIFIED SIDE EFFECT; ANIMAL; DISEASE MODEL; MOUSE; TRANSGENIC MOUSE;

MUS; MUS MUSCULUS;

ALZHEIMER DISEASE; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNIZATION, PASSIVE; MICE; MICE, TRANSGENIC;

EID: 70350755721     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1100/tsw.2009.99     Document Type: Review

References (76)

1. Selkoe, D.J. (1991) The molecular pathology of Alzheimer's disease. Neuron 6, 487-498.
2. Hardy, J. and Allsop, D. (1991) Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol. Sci. 12(10), 383-388.
3. Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., Mant, R., et al. (1991) Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349, 704-706.
4. Levy-Lahad, E., Wijsman, E.M., Nemens, E., Anderson, L., Goddard, K.A., Weber, J.L., Bird, T.D., and Schellenberg, G.D. (1995) A familial Alzheimer's disease locus on chromosome 1. Science 269, 970-973.
5. Haass, C., Schlossmacher, M.G., Hung, A.Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B.L., Lieberburg, I., Koo, E.H., Schenk, D., Teplow, D.B., and Selkoe, D.J. (1992) Amyloid β-peptide is produced by cultured cells during normal metabolism. Nature 359(6393), 322-325.
6. Monsonego, A., Maron, R., Zota, V., Selkoe, D.J., and Weiner, H.L. (2001) Immune hypo-responsiveness to amyloid β-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 98, 10273-10278.
7. Monsonego, A., Zota, V., Karni, A., Krieger, J.I., Bar-Or, A., Bitan, G., et al. (2003) Increased T cell reactivity to amyloid β-protein in older humans and patients with Alzheimer disease. J. Clin. Invest. 112(3), 415-422.
8. Check, E. (2002) Nerve inflammation halts trial for Alzheimer's drug. Nature 415, 462.
9. h2 responses to immunization with β-amyloid. Int. Immunol. 15(4), 505-514.
10. Spooner, E.T., Desai, R.V., Mori, C., Leverone, J.F., and Lemere, C.A. (2002) The generation and characterization of potentially therapeutic Abeta antibodies in mice: differences according to strain and immunization protocol. Vaccine 21, 290-297.
11. McLaurin, J., Cecal, R., Kierstead, M.E., Tian, X., Phinney, A.L., Manea, M., et al. (2002) Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat. Med. 8, 1263-1269.
12. Moir, R.D., Tseitlin, K.A., Soscia, S., Hyman, B.T., Irizarry, M.C., and Tanzi, R.E. (2005) Autoantibodies to redox-modified oligomeric Abeta are attenuated in the plasma of Alzheimer's disease patients. J. Biol. Chem. 280(17), 17458-17463.
13. Weksler, M.E., Relkin, N., Turkenich, R., LaRusse, S., Zhou, L., and Szabo, P. (2002) Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp. Gerontol. 37, 943-948.
14. Xu, S. and Gaskin, F. (1997) Increased incidence of anti-beta-amyloid autoantibodies secreted by Epstein-Barr virus transformed B cell lines from patients with Alzheimer's disease. Mech. Ageing Dev. 94(1-3), 213-222.
15. Du, Y., Dodel, R., Hampel, H., Buerger, K., Lin, S., Eastwood, B., Bales, K., Gao, F., Moeller H.J., Oertel, W., Farlow, M., and Paul, S. (2001) Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology 57(5), 801-805.
16. Maggio, J.E. and Mantyh, P.W. (1996) Brain amyloid-a physicochemical perspective. Brain Pathol. 6, 147-162.
17. Barrow, C.J. and Zagorski, M.G. (1991) Solution structures of beta peptide and its constituent fragments: relation to amyloid deposition. Science 253, 179-182.
18. Soto, C., Castano, E.M., Frangione, B., and Inestrosa, N.C. (1995) The a-helical to b-strand transition in the amino-terminal fragment of the amyloid β-peptide modulates amyloid formation. J. Biol. Chem. 270, 3063.
19. Kirschenbaum, K. and Daggett, V. (1995) pH-dependent conformations of the amyloid beta(1-28) peptide fragment explored using molecular dynamics. Biochemistry 34(23), 7629-7639.
20. Frauenfelder, H., Petsko, G.A., and Tsernoglou, D. (1979) Temperature dependent x-ray diffraction as a probe of protein structural dynamics. Nature 280, 558.
21. Karplus, M. and Petsko, G.A. (1990) Molecular dynamics simulations in biology. Nature 347, 632.
22. Blond, S. and Goldberg, M. (1987) Partly native epitopes are already present on early intermediates in the folding of tryptophan synthase. Proc. Natl. Acad. Sci. U. S. A. 84, 1147.
23. Carlson, J.D. and Yarmush, M.L. (1992) Antibody assisted protein refolding. Biotechnology (N. Y.) 10, 86.
24. Solomon, B. and Balas, N. (1991) Thermostabilization of carboxypeptidase A by interaction with its monoclonal antibodies. Biotechnol. Appl. Biochem. 14, 202.
25. Solomon, B. and Schwartz, F. (1995) Chaperone-like effect of monoclonal antibodies on refolding of heat-denatured carboxypeptidase A. J. Mol. Recogn. 8, 72-76.
26. Solomon, B., Gozanski-Katzav, T., Koppel, R., and Hanan-Aharon, E. (1998) Activity of monoclonal antibodies in prevention of in vitro aggregation of their antigens. In Stability and Stabilization of Biocatalysts. Ballesteros, A., Plou, F.J., Iborra, J.L., and Halling, P.J., Eds. Elsevier, Amsterdam. pp. 183-188.
27. Katzav, T., Hanan, E., and Solomon, B. (1996) Effect of monoclonal antibodies in preventing carboxypeptidase A aggregation. Appl. Biochem. Biotechnol. 2, 227.
28. Solomon, B., Koppel, R., Hanan, E., and Katzav, T. (1996) Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer's β-amyloid peptide. Proc. Natl. Acad. Sci. U. S. A. 93(1), 452-455.
29. Hanan, E. and Solomon, B. (1996) Protective effect of monoclonal antibodies against Alzheimer's β-amyloid aggregation. Amyloid 3, 130-133.
30. Solomon, B., Koppel, R., Frankel, D., and Hanan-Aharon, E. (1997) Disaggregation of Alzheimer β-amyloid by site-directed mAb. Proc. Natl. Acad. Sci. U. S. A. 94, 4109-4112.
31. Frenkel, D., Balass, M., and Solomon, B. (1998) N-terminal EFRH sequence of Alzheimer's β-amyloid peptide represents the epitope of its anti-aggregating antibodies. J. Neuroimmunol. 88, 85-90.
32. Frenkel, D., Balass, M., Kachalsky-Katzir, E., and Solomon, B. (1999) High affinity binding of monoclonal antibodies to the sequential epitope EFRH of β-amyloid peptide is essential for modulation of fibrillar aggregation. J. Neuroimmunol. 95, 136.
33. Van Leuven, F. (2000) Single and multiple transgenic mice as models for Alzheimer's disease. Prog. Neurobiol. 61(3), 305-312.
34. Solomon, B. (2002) Immunological approaches as therapy for Alzheimer's disease. Exp. Opin. Biol. Ther. 2(8), 907-917.
35. Imbimbo, B.P. (2002) β-Amyloid immunization approaches for Alzheimer's disease. Drug Dev. Res. 56, 150-162.
36. Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khank, K., and Kholodenko, D. (1999) Immunization with amyloid-β attenuates Alzheimer's disease-like pathology in the PDAPP mouse. Nature 400, 173-177.
37. Weiner, H.L., Lemere, C.A., Maron, R., Spooner, E.T., Grenfell, T.J., Mori, C., Issazadeh, S., Hancock, W.W., and Selkoe, D.J. (2000) Nasal administration of amyloid-β peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann. Neurol. 48, 567-579.
38. Monsonego, A., Maron, R., Zota, V., Selkoe, D.J., and Weiner, H.L. (2001) Immune hyporesponsiveness to amyloid β-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 98, 10273-10278.
39. Sigurdsson, E.M., Scholtzova, H., Mehta, P.D., Frangione, B., and Wisniewski, T. (2001) Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. Am. J. Pathol. 159, 439-447.
40. Nicolau, C., Greferath, R., Balaban, T.S., Lazarte, J.E., and Hopkins, R.J. (2002) A liposome-based therapeutic vaccine against β-amyloid plaques on the pancreas of transgenic NORBA mice. Proc. Natl. Acad. Sci. U. S. A. 99, 2332-2337.
41. Frenkel, D., Dewachter, I., Van Leuven, F., and Solomon, B. (2003) Reduction of beta-amyloid plaques in brain of transgenic mouse model of Alzheimer's disease by EFRH-phage immunization. Vaccine 21, 1060-1065.
42. Lavie, V., Becker, M., Cohen-Kupiec, R., Yacoby, I., Koppel, R., Wedenig, M., Hutter-Paier, B., and Solomon, B. (2004) EFRH-phage immunization of Alzheimer's disease animal model improves behavioral performance in Morris Water Maze trials. J. Mol. Neurosci. 24, 105-113.
43. Lemere, C.A., Maier, M., Jiang, L., Peng, Y., and Seabrook, T.J. (2006) Amyloid-β immunotherapy for the prevention and treatment of Alzheimer disease: lessons from mice, monkeys, and humans. Rejuvenation Res. 9, 77-84.
44. Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (2000) Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6(8), 916-920.
45. Pfeifer, M., Boncristiano, S., Bondolfi, L., Stalder, A., Delle, T., Staufenbiel, M., Mathews, P.M., and Jucker, M. (2002) Cerebral hemorrhage after passive anti-Aβ immunotherapy. Science 298(5597), 1379.
46. Demattos, R.B., Bales, K.R., Cummins, D.I., Dodart, J.C., Paul, S.M., and Holtzman, D.M. (2001) Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 17, 8850-8855.
47. Asami-Odaka, A., Obayashi-Adachi, Y., Matsumoto, Y., Takahashi, H., Fukumoto, H., Horiguchi, T., Suzuki, N., and Shoji, M. (2005) Passive immunization of the Aβ42(43) C-terminal-specific antibody BC05 in a mouse model of Alzheimer's disease. Neurodegener. Dis. 2(1), 36-43.
48. Carty, N.C., Wilcock, D.M., Rosenthal, A., Grimm, J., Pons, J., Ronan, V., Gottschall, P.E., Gordon, M.N., and Morgan, D. (2006) Intracranial administration of deglycosylated C-terminal-specific anti-Aβ antibody efficiently clears amyloid plaques without activating microglia in amyloid-depositing transgenic mice. J. Neuroinflammation 10, 3.
49. Wilcock, D.M., Rojiani, A., Rosenthal, A., Levkowitz, G., Subbarao, S., Alamed, J., Wilson, D., Wilson, N., Freeman, M.J., Gordon, M.N., and Morgan, D. (2004) Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J. Neurosci. 24(27), 6144-6151.
50. Lambert, M.P., Velasco, P.T., Chang, L., Viola, K.L., Fernandez, S., Lacor, P.N., Khuon, D., Gong, Y., Bigio, E.H., Shaw, P., De Felice, F.G., Krafft, G.A., and Klein, W.L. (2007) Monoclonal antibodies that target pathological assemblies of Aβ. J. Neurochem. 100, 23-35.
51. Boulianne, G.L., Hozumi, N., and Shulman, M.J. (1984) Production of functional chimaeric mouse/human antibody. Nature 312, 643-646.
52. Jones, P.T., Dear, P.H., Foote, J., Neuberger, M.S., and Winter, G. (1986) Replacing the complementary-determining regions in a human antibody with those from a mouse. Nature 321, 522-525.
53. Weksler, M.E., Relkin, N., Turkenich, R., LaRusse, S., Zhou, L., and Szabo, P. (2002) Patients with Alzheimer's disease have lower levels of serum anti-amyloid peptide antibodies than healthy individuals. Exp. Gerontol. 37(7), 943-948.
54. Dodel, R., Hampel, H., Depboylu, C., Lin, S., Gao, F., Schock, S., Jackel, S., Wei, X., Buerger, K., Hoft, C., Hemmer, B., et al. (2002) Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease. Ann. Neurol. 52(2), 253-256.
55. Du, Y., Wei, X., Dodel, R., Sommer, N., Hampel, H., Gao, F., Ma, Z., Zhao, L., Oertel, W.H., and Farlow, M. (2003) Human anti-beta-amyloid antibodies block beta-amyloid fibril formation and prevent beta-amyloid-induced neurotoxicity. Brain 126(Pt 9), 1935-1939.
56. Dalakas, M.C. (2002) Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies. Neurology 59(12 Suppl 6), S13-21.
57. Istrin, G., Bosis, E., and Solomon, B. (2006) Intravenous immunoglobulin enhances the clearance of fibrillar amyloid-beta peptide. J. Neurosci. Res. 84(2), 434-443.
58. Mohajeri, M.H. and Lichtlen, P. (2008) Antibody-based approaches in Alzheimer's research: safety, pharmacokinetics, metabolism, and analytical tools. J. Neurochem. 104, 859-874.
59. Dodel, R.C., Hampel, H., and Du, Y. (2003) Immunotherapy for Alzheimer's disease. Lancet Neurol. 2, 215-220.
60. Banks, W.A., Terrell, B., Farr, S.A., Robinson, S.M., Nonaka, N., and Morley, J.E. (2002) Passage of amyloid β protein antibody across the blood-brain barrier in a mouse model of Alzheimer's disease. Peptides 23, 2223-2226.
61. Bard, F., Barbour, R., Cannon, C., Carretto, R., Fox, M., Games, D., et al. (2003) Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc. Natl. Acad. Sci. U. S. A. 100(4), 2023-2028.
62. Webster, S.D., Galvan, M.D., Ferran, E., Garzon-Rodriguez, W., Glabe, C.G., and Tenner, A.J. (2001) Antibody-mediated phagocytosis of the amyloid beta-peptide in microglia is differentially modulated by C1q. J. Immunol. 166, 7496.
63. Lue, L.-F. and Walker, D.G. (2002) Modeling Alzheimer's disease immune therapy mechanisms: interactions of human postmortem microglia with antibody-opsonized amyloid beta peptide. J. Neurosci. Res. 70, 599-610.
64. McLaurin, J., Cecal, R., Kierstead, M.E., Tian, X., Phinney, A.L., Manea, M., French, J.E., Lambermon, M.H.L., Darabie, A.A., Brown, M.E., et al. (2002) Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4- and inhibit cytotoxicity and fibrillogenesis. Nat. Med. 8, 1263-1269.
65. Lombardo, J.A., Stern, E.A., McLellan, M.E., Kajdasz, S.T., Hickey, G.A., Bacskai, B.J., and Hyman, B.T. (2003) Amyloid-β antibody treatment leads to rapid normalization of plaque-induced neuritic alterations. J. Neurosci. 23, 10879-10883.
66. Bacskai, B.J., Kajdasz, S.T., Christie, R.H., Carter, C., Games, D., Seubert, P., Schenk, D., and Bradley, H.T. (2001) Imaging of amyloid-β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat. Med. 7(3), 369-372.
67. Bacskai, B.J., Kajdasz, S.T., McLellan, M.E., Games, D., Seubert, P., Schenk, D., and Hyman, B.T. (2002) Non-fc-mediated mechanisms are involved in clearance of amyloid-β in vivo by immunotherapy. J. Neurosci. 15, 7873-7878.
68. Frenkel, D., Solomon, B., and Benhar, I. (2000) Modulation of Alzheimer's β-amyloid neurotoxicity by site-directed single-chain antibody. J. Neuroimmunol. 106, 23-31.
69. Solomon, B. and Frenkel, D. (2002) Filamentous phage as vector-mediated antibody delivery to the brain. Proc. Natl. Acad. Sci. U. S. A. 99(8), 5675-5679.
70. Liu, R., Yuan, B., Emadi, S., Zameer, A., Schulz, P., McAllister, C., Lyubchenko, Y., Goud, G., and Sierks, M. R. (2004) Single chain variable fragments against beta-amyloid (Aβ) can inhibit Aβ aggregation and prevent Aβ-induced neurotoxicity. Biochemistry 43, 6959-6967.
71. Levites, Y., Jansen, K., Smithson, L.A., Dakin, R., Holloway, V.M., Das, P., and Golde, T.E. (2006) Intracranial adeno-associated virus-mediated delivery of anti-pan amyloid beta, amyloid beta40, and amyloid beta42 single-chain variable fragments attenuates plaque pathology in amyloid precursor protein mice. J. Neurosci. 26, 11923-11928.
72. Fukuchi, K., Tahara, K., Kim, H.D., Maxwell, J.A., Lewis, T.L., Accavitti-Loper, M.A., Kim, H., Ponnazhagan, S., and Lalonde, R. (2006) Anti-Aβ single-chain antibody delivery via adeno-associated virus for treatment of Alzheimer's disease. Neurobiol. Dis. 23, 502-511.
73. Das, P., Howard, V., Loosbrock, N., Dickson, D., Murphy, M.P., and Golde, T.E. (2003) Amyloid-β immunization effectively reduces amyloid deposition in FcRγ-/- knock-out mice. J. Neurosci. 23, 8532-8538.
74. DeMattos, R.B., Bales, K.R., Cummins, D.J., Paul, S.M., and Holtzman, D.M. (2002) Brain to plasma amyloid-β efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 295, 2264-2267.
75. Lemere, C.A., Spooner, E.T., LaFrancois, J., Maleste, B., Mori, C., Leverone, J.F., Matsuoka, Y., Taylor, J.W., DeMattos, R.B., Holtzman, D.M., Clements, J.D., Selkoe, D.J., and Duff, K.E. (2003) Evidence for peripheral clearance of cerebral Aβ protein following chronic, active Aβ immunization in PSAPP mice. Neurobiol. Dis. 14, 10-18.
76. Oddo, S., Caccamo, A., Shepherd, J.D., Murphy, M.P., Golde, T.E., Kayed, R., Metherate, R., Mattson, M.P., Akbari, Y., and LaFerla, F.M. (2003) Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39(3), 409-421.